Literature DB >> 7553885

Phosphorylation of src family lck tyrosine kinase following interleukin-12 activation of human natural killer cells.

C Pignata1, K V Prasad, M Hallek, B Druker, C E Rudd, M J Robertson, J Ritz.   

Abstract

Interleukin-12 (IL-12) is a heterodimeric cytokine that augments the cytolytic activity of human NK cells and T cells but has little mitogenic activity on resting lymphocytes. The intracellular signaling pathways involved in NK cell activation by IL-12 have not been fully characterized. In the present studies we found that IL-12 induces tyrosine phosphorylation of a 56-kDa protein, identified in Western blot experiments as p56lck, in resting NK cells. IL-12 was active in the range of 0.1 to 1000 U/ml, with maximal activity between 10 and 100 U/ml (30 and 300 pM). The maximal effect was noted 5 min after stimulation and was almost completely inhibited by genistein. IL-12 induced similar effects in resting and IL-2 activated NK cells. Following IL-12 stimulation of resting NK cells, immunoprecipitated lck kinase exhibited increased in vitro autophosphorylation activity 5 and 10 min after activation. Several additional substrates were phosphorylated in vitro following IL-12 stimulation, including proteins of 70 and 110 kDa. These studies indicate that lck tyrosine kinase is involved in the IL-12 signaling pathway in human NK cells. As the primary functional effect of IL-12 on resting NK cells is the enhancement of cytolytic activity and secretory function rather than cell proliferation, these findings suggest that lck tyrosine kinase is involved in these signaling pathways in human NK cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7553885     DOI: 10.1006/cimm.1995.1207

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  5 in total

1.  IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.

Authors:  Robin Parihar; Julie Dierksheide; Yan Hu; William E Carson
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

2.  Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.

Authors:  Hideo Tanaka; Shizuka Nakashima; Miyuki Usuda
Journal:  Int J Hematol       Date:  2012-07-06       Impact factor: 2.490

Review 3.  Large granular lymphocytosis during dasatinib therapy.

Authors:  Zhi-Yuan Qiu; Wei Xu; Jian-Yong Li
Journal:  Cancer Biol Ther       Date:  2013-12-18       Impact factor: 4.742

4.  Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases.

Authors:  M Schaeffer; M Schneiderbauer; S Weidler; R Tavares; M Warmuth; G de Vos; M Hallek
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

5.  Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.

Authors:  Dong Hwan Kim; Suzanne Kamel-Reid; Hong Chang; Robert Sutherland; Chul Won Jung; Hyeoung-Joon Kim; Je-Jung Lee; Jeffrey H Lipton
Journal:  Haematologica       Date:  2008-12-09       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.